Company: DRTSW
Filing Date: 2025-04-28
Form Type: 424B5
Source: 0001213900-25-035799
Chunk: 64

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 424B5
Chunk 64
---
us supplements.

<div align='center'>OFFER AND LISTING DETAILS</div>

Our ordinary shares and warrants
have been traded on the Nasdaq Capital Market under the symbols “DRTS” and “DRTSW” since March 8, 2022.

<div align='center'>USE OF PROCEEDS</div>

Unless otherwise indicated
in an accompanying prospectus supplement, the net proceeds from the sale of securities will be used for general corporate purposes, including
research and development related purposes in connection with our product candidates and for potential commercialization of our product
candidates.

<div align='center'>DESCRIPTION OF ORDINARY SHARES AND EXISTING WARRANTS</div>

Our authorized share capital
consists of 362,116,800 ordinary shares, no par value, of which 69,275,603 ordinary shares were issued and outstanding as of March 31,
2023.

All of our issued and outstanding
ordinary shares have been validly issued, fully paid and non-assessable. Our ordinary shares are not redeemable and do not have any preemptive
rights.

In connection with our business
combination that closed on March 7, 2022, we issued 15,891,984 existing warrants, each entitling its holder to purchase one ordinary share
at an initial exercise price equal to $11.50 per share.

For a further description
of our ordinary shares and existing warrants, see Exhibit 2.1 to our Annual Report.

<div align='center'>7

DESCRIPTION OF WARRANTS</div>

We may issue warrants to purchase
ordinary shares. Warrants may be issued independently or together with any other securities and may be attached to, or separate from,
such securities. Each series of warrants will be issued under a separate warrant agreement, which may be entered into between us and a
warrant agent specified in an applicable prospectus supplement relating to a particular series of warrants. Any such warrant agent will
act solely as our agent and will not assume any obligation or relationship of agency for or with holders or beneficial owners of warrants.
We may also choose to act as our own warrant agent. The terms of any warrants to be issued and a description of the material provisions
of the applicable warrant agreement will be set forth in the applicable prospectus supplement.

The applicable prospectus
supplement will describe the following terms of any warrants in respect of which this prospectus is being delivered:

| ● | the title of such warrants; |

| ● | the aggregate number of such 
 warrants